



## FOR IMMEDIATE RELEASE

### Exemplar LIMS Accelerates Mitomics CLIA Certification and Serves as Foundation of Operations

**Baltimore, MD – November 28, 2011** – Mitomics Inc., a pioneer in the development of molecular tests based on the mitochondrial genome, has implemented Sapio Sciences Exemplar LIMS where it serves a foundational role in the operations of Mitomics. Phase One of the project was implemented in an unprecedented 3 months and encompassed a large scope including a fully electronic process for physician test requests of the Prostate Core Mitomic Test (PCMT™), to detailed lab processing workflows. Since then the lab operations have been refined and the Exemplar LIMS has been programmed for data exchange with Mitomics partners using the industry standard HL7 format

The full range of operations that Exemplar supports includes:

- A series of HIPAA/HITECH-compliant Mitomics branded custom web interfaces for:
  - Sales support, enabling physician registration in Exemplar and viewing physician activity
  - Ordering physicians, facilitating test requisition, status tracking, and report delivery
  - Logistics support, expediting the dispatch and delivery of PCMT collection kits to participating pathology labs across the country.
- Mitomics branded requisition and report PDF generation
- Complete workflow tracking (Electronic Lab Notebook) and documentation of sample processing from DNA extraction to PCR including quantitative assessments, reagent calculations, etc. as part of CLIA compliance
- Sample management features
- Assay data loading and management completely within the LIMS
- Complete implementation of multi-level and electronic test result approvals
- Billing integration with third party provider for expedient processing of payments
- Health records exchange in standard HL7 format for requisition and test results exchange with third parties

“The fact that a project of this scope was completed in highly compressed timeframe is a testament to the ease with which Exemplar can be adapted to any environment, and to the skills of our staff who worked on the implementation,” says Eric Price, Implementation Team Lead at Sapio. “Mitomics has been a great partner and we look forward to our continued support of their diagnostics business as they bring new and innovative diagnostic products to market”.

“We have been very pleased with Sapio Sciences Exemplar LIMS system, particularly the ability of it to adapt to our business in such a rapid fashion. With the anticipated launch of further Mitomic tests over the coming months, we are confident that these new Mitomic tests will be efficiently integrated into our Exemplar LIMS system, including lab work flows, order entry, reporting, and data exchange”, says Jason Dulude, Chief Financial Officer at Mitomics.

For more information or to schedule a product demonstration, visit <http://www.SapioSciences.com>.

#### About Sapio Sciences Llc

Sapio Sciences is a leading provider of LIMS and Data Management software, enabling scientists to manage samples, protocols, assay data and clinical trials. Exemplar LIMS breaks new ground in its breadth of functionality and ease of configuration. With built-in Sample Management, Step-by-Step protocol tracking (ELN), data management and integrated analytics, Exemplar LIMS addresses the full life cycle of samples from receipt to processing and analysis. Sapio will continue to lead in ease of use and breadth of functionality across its product line, enabling organizations to reduce costs while increasing productivity and efficiency of both laboratories and researchers alike. Sapio has strong working relationships with leading platform vendors such as Affymetrix, Illumina and Applied Biosystems ensuring compatibility with technology from these leading companies.

#### About Mitomics, Inc.

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests that address significant unmet needs in oncology and gynecology, including those for the early detection of prostate and breast cancer, as well as a test for endometriosis. Mitomics currently markets the Prostate Core Mitomic Test™, a highly accurate laboratory developed test for



detecting the absence or presence of cancerous cells using existing prostate biopsy tissue, and plans to launch several additional breakthrough molecular tests based on its Mitomic Technology™ in the coming years. The company is headquartered in Thunder Bay, Ontario, Canada. For more information, please visit [www.mitomicsinc.com](http://www.mitomicsinc.com).

**For Further Information:**

Anmarie Hazelton

Sapio Sciences LLC

Email: [ahazelton@sapiosciences.com](mailto:ahazelton@sapiosciences.com)